Immunogenicity and Safety of Hepatitis B Virus (HBV) Vaccine With a Toll-Like Receptor 9 Agonist Adjuvant in HBV Vaccine-Naïve People With Human Immunodeficiency Virus.

Autor:	Marks, Kristen M, Kang, Minhee, Umbleja, Triin, Avihingsanon, Anchalee, Sugandhavesa, Patcharaphan, Cox, Andrea L, Vigil, Karen, Perazzo, Hugo, Price, Jennifer C, Katsidzira, Leolin, Vernon, Christina, Alston-Smith, Beverly, Sherman, Kenneth E, Team, ACTG 5379 Study
Předmět:	HIV infections VACCINES CONFIDENCE intervals VIRAL hepatitis VACCINE immunogenicity TREATMENT effectiveness COMPARATIVE studies HIGHLY active antiretroviral therapy DESCRIPTIVE statistics CD4 lymphocyte count RESEARCH funding TOLL-like receptors PATIENT safety
Zdroj:	Clinical Infectious Diseases; Aug2023, Vol. 77 Issue 3, p414-418, 5p
Abstrakt:	In this international, multicenter open-label study (ACTG A5379) of HepB-CpG vaccine in people with human immunodeficiency virus (HIV) without prior hepatitis B virus (HBV) vaccination, all 68 participants achieved HBV seroprotective titers after the 3-dose series in the primary analysis. No unexpected safety issues were observed. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu